-- Arovella has entered into a global, exclusive license with University of North CarolinaLineberger Comprehensive Cancer Center to incorporate a novel armouring cytokinetechnology (IL-12-TM) for its CAR-iNKT cell platform
-- Arovella is the only company globally developing IL-12-TM armoured CAR-iNKT cells
-- This armouring cytokine technology:
---- results in a ten-fold increase in circulating CAR-iNKT cell numbers in animal models forsolid tumours
---- significantly improved CAR-iNKT anti-tumour activity
---- significantly improved overall survival in animal models
---- enhances CAR-iNKT cells to potentially treat a range of solid tumour types
-- Patent applications filed to protect the technology until at least 2043
-- Investor webinar is scheduled for 11 am AEDT on Wednesday, 31st January.
MELBOURNE, AUSTRALIA 30 January 2024: Arovella Therapeutics Ltd (ASX: ALA) has signed a global, exclusive License Agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) to incorporate UNC Lineberger’s novel IL-12-TM (cytokine technology) into Arovella’s CAR-iNKT cell therapy platform. The technology was developed by Professor Gianpietro Dotti, a pioneer of CAR-iNKT cells, and was recently published in the prestigious peer-reviewed journal Nature Communications.
Arovella’s CEO and MD, Dr Michael Baker, commented: “We are incredibly excited to license the IL-12-TM technology from Professor Dotti’s laboratory for use with our CAR-iNKT cell platform. The data supporting solid tumours is compelling and will see Arovella enhance its solid tumour pipelines and effectiveness.”
For more information, download the attached PDF.
Download this document
